Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer (OTT-19-06)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04676516
Recruitment Status : Not yet recruiting
First Posted : December 21, 2020
Last Update Posted : February 23, 2021
Sponsor:
Collaborators:
Ontario Institute for Cancer Research
GlaxoSmithKline
London Regional Cancer Program, Canada
Hamilton Health Sciences Corporation
Information provided by (Responsible Party):
Ottawa Hospital Research Institute

Brief Summary:
This is a Phase II Randomized Window of Opportunity Trial Evaluating Clinical and Biological effects of PRMT5 inhibitor, GSK3326595, in Early Stage Breast Cancer

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: GSK3326595 Phase 2

Detailed Description:
This is a phase II, randomized, open label, multi-center, parallel design, window of opportunity trial in up to 60 patients with early stage Hormone Receptor (HR) positive breast cancer evaluating GSK3326595. In a 2:1 randomization, patients will receive GSK3326595:no treatment for 15 +/- 3 days prior to breast surgery. There is no placebo in this trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Phase II, randomized, open label, multi-center, parallel design, window of opportunity trial
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Randomized Window of Opportunity Trial Evaluating Clinical and Biological Effects of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer
Estimated Study Start Date : March 21, 2021
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Experimental Arm
Participants randomized to treatment with GSK3326595 will be requested to take 15 +/- 3 days of the medication at the dose of 200 mg orally daily (2 capsules of 100 mg) prior to their breast cancer surgery or repeat biopsy. GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
Drug: GSK3326595
GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
Other Name: PRMT5 inhibitor

No Intervention: No Intervention Arm
Participants will receive no treatment for 15 +/- 3 days prior to breast surgery. There is no placebo in this trial.



Primary Outcome Measures :
  1. Complete cell cycle arrest (CCCA) [ Time Frame: 2 years ]
    The primary outcome is the proportion of patients who achieve a Complete Cell Cycle Arrest (CCCA), defined as a reduction in the proportion of Ki67 positively staining cells to ≤ 2.7%.


Secondary Outcome Measures :
  1. Rate of complete cell cycle arrest (CCCA) in patients with wild-type TP53 [ Time Frame: 2 years ]
    The secondary outcome is to assess whether PRMT5 inhibition preferentially results in CCCA in patients with wild-type TP53.

  2. Assess whether PRMT5 inhibition results in reduced expression of ER-α signaling compared to patients with no treatment based on gene expression analysis. [ Time Frame: 2 years ]
    A secondary outcome is to assess whether PRMT5 inhibition results in reduced expression of ER-α signaling.

  3. Assess whether PRMT5 inhibition results in changes in breast-cancer stem cell signature particularly FOXP1 compared to patients with no treatment based on gene expression analysis [ Time Frame: 2 years ]
    A secondary outcome is to assess whether PRMT5 inhibition results in changes in breast-cancer stem cell signature particularly FOXP1.

  4. Perform molecular analysis to identify immunomodulatory effects of GSK3326595 determined by abundance of different immune cells in tumor (CD4, CD8, NK cells, macrophages, etc) in the tumors treated with GSK3326595 alone versus the untreated tumours. [ Time Frame: 2 years ]
    A secondary outcome is to identify the immunomodulatory effects of GSK3326595, by performing exploratory analyses.


Other Outcome Measures:
  1. Rate of alternative splicing of Murine Double Minute 4 (MDM4) [ Time Frame: 2 years ]
    A tertiary outcome is to assess if PRMT5 inhibition results in alternative splicing of MDM4.

  2. % of response in participants with high Programmed Cell Death 4 (PDCD4) expression and Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) loss [ Time Frame: 2 years ]
    A tertiary outcome is to assess whether PRMT5 inhibition results in preferential response in patients with high PDCD4 expression and CDKN2A loss.

  3. % of response in participants with defects in homologous recombination DNA repair [ Time Frame: 2 years ]
    A tertiary outcome is to assess whether PRMT5 inhibition results in preferential response in patients with defects in homologous recombination DNA repair.

  4. % of response in participants with defects in Cyclin D (CCND)/ Cyclin-dependent kinases (CDK) pathway [ Time Frame: 2 years ]
    A tertiary outcome is to assess whether PRMT5 inhibition results in preferential response in patients with defects in CCND/CDK pathway.

  5. % of response in patients with defects in phosphatidylinositol-3-kinase (PI3K)/Serine-threonine protein kinase 1 (AKT) pathway [ Time Frame: 2 years ]
    A tertiary outcome is to assess whether PRMT5 inhibition results in preferential response in patients with defects in PI3K/AKT pathway.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Female post-menopausal participants
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Female patients with newly diagnosed histologically confirmed primary invasive breast cancer currently not undergoing any treatment while awaiting surgery
  2. Operable breast cancer as assessed by treating surgical oncologist
  3. Tumor ≥ 1.0 cm by palpation or imaging
  4. ER or PR positive (≥1%) breast adenocarcinoma
  5. Her2 negative as per ASCO 2018 guidelines 61
  6. Invasive ductal or lobular carcinoma, invasive carcinoma Not Otherwise Specified (NOS)
  7. ECOG PS 0-2 (Appendix A)
  8. Post-menopausal and not of child bearing potential as defined as: by having 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40mlU/ml and estradiol < 20 pg/mL or have had documented surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks prior.
  9. Able to provide written informed consent for the study.
  10. Able to swallow and retain orally administered medication.

Exclusion Criteria:

  1. Locally Advanced or metastatic breast cancer
  2. Prior therapy with chemotherapy or planned neoadjuvant chemotherapy
  3. Prior hormonal therapy including tamoxifen, aromatase inhibitors
  4. Pre-dominant histology other than invasive ductal or lobular carcinoma
  5. Concomitant other invasive malignancy.
  6. Hgb < 100 g/L, Platelets < 100 x 10^9 per liter, Absolute Neutrophil Count < 1.5 x 10^9/L
  7. Bilirubin ≥ 1.5 times Upper Limit Normal (ULN)
  8. ALT ≥ 2.5 times ULN
  9. Albumin < 25 g/L
  10. INR/PTT > 1.5 times ULN
  11. Creatinine clearance calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation of less than 50 mL/min/1.73m2.
  12. Cardiac abnormalities as evidenced by any of the following:

    1. Baseline QTcF interval ≥ 480 msec
    2. Clinically significant conduction abnormalities or arrhythmias
    3. Presence of cardiac pacemaker or defibrillator with a paced ventricular rhythm limiting ECG analysis.
    4. History or evidence of current ≥ Class II congestive heart failure as defined by New York Heart Association (NYHA).
    5. History of acute coronary syndromes (including unstable angina and myocardial infarction), coronary angioplasty, or stenting within the past 3 months.
    6. Clinically significant cardiomegaly, ventricular hypertrophy, or cardiomyopathy.
  13. Any serious known immediate or delayed hypersensitivity reaction(s) to GSK3326595, or idiosyncrasy to drugs chemically related to the investigational drugs.
  14. Current use of a prohibited medication or planned use of any forbidden medications during treatment with GSK3326595, which include chemotherapy, immunotherapy, biologic therapy, investigational therapy, or hormonal therapy (other than corticosteroids) while on treatment in this study. GSK3326595 should not be co-administered with potent inhibitors of either BCRP or Pgp such inhibitors include cyclosporine, tacrolimus, and ketoconazole
  15. Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption, such as malabsorption syndrome, chronic gastrointestinal disease, or major resection of the stomach and/or bowels that could preclude adequate absorption of the study medication.
  16. Severe, uncontrolled systemic disease (respiratory, cardiac, renal, hepatic, bleeding)
  17. Currently active liver or biliary disease
  18. History of active HIV, Hepatitis B or C infection.
  19. Any other criteria which, in the investigator's opinion, renders the patient ineligible to be on study.
  20. Subjects with signs/symptoms suggestive of COVID-19 or known COVID-19 positive contacts in the past 14 days would be tested as per local Public Health and/or Institutional Guidelines. If patients are COVID-19 positive at the time of screening, they would be excluded from the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04676516


Contacts
Layout table for location contacts
Contact: John F. Hilton, MD 613-737-7700 ext 70170 jfhilton@toh.ca
Contact: Arif A. Awan, MD 613-737-7700 ext 70179 aawan@toh.ca

Sponsors and Collaborators
Ottawa Hospital Research Institute
Ontario Institute for Cancer Research
GlaxoSmithKline
London Regional Cancer Program, Canada
Hamilton Health Sciences Corporation
Investigators
Layout table for investigator information
Principal Investigator: John F. Hilton, MD The Ottawa Hospital Cancer Centre
Layout table for additonal information
Responsible Party: Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier: NCT04676516    
Other Study ID Numbers: OTT-19-06
First Posted: December 21, 2020    Key Record Dates
Last Update Posted: February 23, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Researchers may contact Dr. John Hilton for specific requests.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ottawa Hospital Research Institute:
Window of Opportunity
PRMT5 inhibitor
GSK3326595
Early Stage Breast Cancer
Hormone Receptor (HR) positive breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases